Wisp

About Wisp

Wisp has operated as a direct-to-consumer telehealth platform since 2018, originally building its reputation as the largest women’s telehealth platform in the United States. The company has since expanded into GLP-1 weight management, offering both brand-name and compounded semaglutide at price points ranging from $199-$399 per month. Wisp’s entry into the weight loss space leverages the clinical infrastructure it developed for sexual health, including STI testing and prescription fulfillment, giving it a logistics advantage many newer competitors lack.

On Trustpilot, Wisp holds a 4.0 rating across 10,900+ reviews, a solid volume that speaks to a large and active user base. However, the company carries a D- rating with the BBB, which our editorial team flags as a point of concern. The gap between customer sentiment on Trustpilot and the BBB grade often indicates unresolved complaint patterns rather than widespread dissatisfaction, but prospective patients should be aware of it before enrolling.

Clinically, Wisp pairs its GLP-1 prescriptions with metabolic support capsules and optional lab testing, including panels originally designed for its sexual health services. The metabolic support add-on is a differentiator worth noting: while many telehealth providers simply prescribe medication, Wisp attempts to address nutritional gaps that can arise during rapid weight loss. That said, the overall clinical support model lands in the medium tier — patients receive asynchronous provider access but should not expect the intensive coaching or dietitian consultations offered by higher-touch competitors.

Wisp’s strongest advantage is its women-centered care model. The platform understands hormonal health, reproductive considerations, and the specific metabolic challenges women face during weight management. For female patients who want a provider already fluent in women’s health, Wisp offers a level of contextual expertise that generalist telehealth platforms simply do not match. The company also provides discreet packaging and shipping, a feature it perfected in its original sexual health business.

Where Wisp falls short is in clinical depth for weight management specifically. The platform does not offer tirzepatide, limits its GLP-1 options compared to specialist providers, and its medium-support model means patients navigating side effects or dose titration may find communication slower than expected. For women seeking a familiar, trusted platform with reasonable pricing and adequate clinical support, Wisp is a credible option — but patients wanting intensive medical oversight should look at higher-support alternatives.

Wisp GLP-1 Medications

At a Glance